Los puntos clave no están disponibles para este artículo en este momento.
Last year the Cochrane team, with the help of the BMJ’s open data campaign, finally got access to full clinical study reports on neuraminidase inhibitors. Tom Jefferson and Peter Doshi explain what the new systematic review found and how a series of failures meant that decisions about these drugs were made without the full evidence
Jefferson et al. (Wed,) studied this question.